Elevance Health stock analysis
Elevance Health passes 4 of 8 fundamental tests, a score of 5/10. On the daily chart it is in an uptrend, RSI 67, 2% below its 52-week high: uptrend, no fresh entry: wait for a pullback or breakout. Its own volatility puts the likely range at $386.71–$474.28 a month from now and $300.72–$609.89 in a year (68% bands).
Fundamentals 5/10
- Market cap
- $92.9 B
- P/E · forward
- 19.0 · 14.5
- PEG · P/B
- 1.4 · 2.1
- ROE · net margin
- +11% · +2%
- Revenue · earnings growth
- +1% · -13%
- Debt / equity
- 69%
- Dividend · beta
- 1.6% · 0.7
- Next results
- 21 Oct 2026
- ✕ ROE above 15%
- ✕ Net margin above 10%
- ✕ Revenue growing over 10%
- ✕ Earnings growing
- ✓ Debt/equity under 100%
- ✓ Positive free cash flow
- ✓ Forward P/E under trailing (earnings expected up)
- ✓ PEG under 2
Swing technicals (daily)
- Trend
- up · 50d above 200d
- RSI(14)
- 67
- 20 / 50 / 200-day avg
- $404.68 / $403.84 / $369.22
- 20-day breakout
- above $434.00 · below $375.74
- ATR(14)
- $10.25 (2.4% a day)
- 52-week range
- $274.84 – $436.24
- Return 3m · 6m · 1y
- +12% · +33% · +23%
What the price could do
| In | Likely range (68%) |
|---|---|
| 1 mo | $386.71 – $474.28 (-10% / +11%) |
| 3 mo | $358.87 – $511.07 (-16% / +19%) |
| 6 mo | $333.53 – $549.90 (-22% / +28%) |
| 1 year | $300.72 – $609.89 (-30% / +42%) |
Analysts (21): buy, mean target $451.71 (+5%)
From its own volatility (35% a year), no drift assumed: what its swings allow, not a forecast.
Elevance Health news · last two days
News lean: Neutral- 37h agoUnveiling Elevance Health (ELV) Q3 Outlook: Wall Street Estimates for Key MetricsZacks
- 2d agoElevance Q3 Earnings Preview: Will Lower Premiums Weigh on Results?Zacks
- 4d agoElevance Health stock pre-market at EUR 380.20Ad Hoc News
- 4d agoElevance Health Inc.DL-Notes 2024(24/26) BondMarkets Insider
- 6d agoGuggenheim raises target for Elevance Health stock to USD 460Ad Hoc News
Its order flow and footprint, the AI read of every headline, the expected move, and your own holdings beside it, with your broker connected.
Information and analytics for education only, not investment advice or a recommendation to buy or sell. Alephix Intelligence is not registered with SEBI as an investment adviser or research analyst. Prices may be delayed; figures come from public market data.